Avanzini Z, Bellogini G C, Brusoni B, Ciampani N, Dei Cas L, Gazzola U, Maggi G C, Mangiavacchi M, Metra M, Pinca L
Arzneimittelforschung. 1986 Feb;36(2A):394-7.
50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition. Ibopamine was administered alone or in combination with traditional therapy mainly at a dose of 100 mg t.i.d. Clinical scores and NYHA (New York Heart Association) functional classes improved. Biochemical parameters showed no adverse modifications. Mild transient side-effects probably related to ibopamine occurred in two patients.
